A detailed history of Morgan Stanley transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Morgan Stanley holds 27,432 shares of PDSB stock, worth $57,332. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,432
Previous 73,988 62.92%
Holding current value
$57,332
Previous $216,000 51.85%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.93 - $4.23 $136,409 - $196,931
-46,556 Reduced 62.92%
27,432 $104,000
Q2 2024

Oct 17, 2024

BUY
$2.55 - $4.02 $3,103 - $4,892
1,217 Added 1.67%
73,988 $216,000
Q2 2024

Aug 14, 2024

BUY
$2.55 - $4.02 $3,103 - $4,892
1,217 Added 1.67%
73,988 $216,000
Q1 2024

Oct 17, 2024

SELL
$3.85 - $6.59 $4,685 - $8,020
-1,217 Reduced 1.64%
72,771 $288,000
Q1 2024

Aug 16, 2024

SELL
$3.85 - $6.59 $47,643 - $81,551
-12,375 Reduced 14.53%
72,771 $288,000
Q1 2024

May 15, 2024

SELL
$3.85 - $6.59 $47,643 - $81,551
-12,375 Reduced 14.53%
72,771 $288,000
Q4 2023

Aug 16, 2024

BUY
$3.95 - $6.58 $44,074 - $73,419
11,158 Added 15.08%
85,146 $423,000
Q4 2023

Feb 13, 2024

BUY
$3.95 - $6.58 $64,495 - $107,438
16,328 Added 23.73%
85,146 $423,000
Q3 2023

Nov 15, 2023

BUY
$4.8 - $6.4 $7,425 - $9,900
1,547 Added 2.3%
68,818 $347,000
Q2 2023

Aug 14, 2023

SELL
$5.03 - $9.9 $184,042 - $362,231
-36,589 Reduced 35.23%
67,271 $338,000
Q1 2023

May 15, 2023

SELL
$5.68 - $11.99 $680,890 - $1.44 Million
-119,875 Reduced 53.58%
103,860 $638,000
Q4 2022

Feb 14, 2023

BUY
$3.28 - $13.2 $683,273 - $2.75 Million
208,315 Added 1350.94%
223,735 $2.95 Million
Q3 2022

Nov 14, 2022

BUY
$2.97 - $5.79 $3,115 - $6,073
1,049 Added 7.3%
15,420 $46,000
Q2 2022

Oct 27, 2022

SELL
$3.05 - $6.68 $6,874 - $15,056
-2,254 Reduced 13.56%
14,371 $52,000
Q2 2022

Aug 15, 2022

SELL
$3.05 - $6.68 $6,874 - $15,056
-2,254 Reduced 13.56%
14,371 $52,000
Q1 2022

Oct 27, 2022

BUY
$4.78 - $8.43 $10,774 - $19,001
2,254 Added 15.68%
16,625 $103,000
Q1 2022

May 13, 2022

SELL
$4.78 - $8.43 $18,283 - $32,244
-3,825 Reduced 18.7%
16,625 $103,000
Q4 2021

Feb 14, 2022

BUY
$7.76 - $14.35 $114,258 - $211,289
14,724 Added 257.14%
20,450 $166,000
Q3 2021

Nov 15, 2021

BUY
$9.33 - $17.08 $53,423 - $97,800
5,726 New
5,726 $85,000

Others Institutions Holding PDSB

About PDS Biotechnology Corp


  • Ticker PDSB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,458,700
  • Market Cap $59.5M
  • Description
  • PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...
More about PDSB
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.